Cover Image
市場調查報告書

全球癌症免疫療法市場 (∼2027年):單株抗體,細胞激素、免疫調節藥物,免疫查核點抑制劑,細胞療法,腫瘤溶解性病毒免疫療法,肺癌,乳癌,大腸癌,黑色素瘤,前列腺癌,頭頸癌

Global Cancer Immunotherapy Market to 2027: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck Cancers

出版商 Visiongain Ltd 商品編碼 602846
出版日期 內容資訊 英文 165 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症免疫療法市場 (∼2027年):單株抗體,細胞激素、免疫調節藥物,免疫查核點抑制劑,細胞療法,腫瘤溶解性病毒免疫療法,肺癌,乳癌,大腸癌,黑色素瘤,前列腺癌,頭頸癌 Global Cancer Immunotherapy Market to 2027: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck Cancers
出版日期: 2017年12月11日 內容資訊: 英文 165 Pages
簡介

全球癌症免疫療法市場2016年達519億美元規模。該市場今後將以12.6%的年複合成長率擴大。

本報告提供全球癌症免疫療法市場相關調查,市場概要和各市場區隔,各地區趨勢,及加入此市場的主要企業的簡介等彙整資料。

第1章 本報告概要

第2章 簡介

第3章 2017∼2027年的市場預測

第4章 至2027年的各技術市場預測

  • 概要
  • 單株抗體
  • 細胞激素、免疫調節藥物
  • 其他 (免疫查核點抑制劑,細胞療法,腫瘤溶解性病毒免疫療法)

第5章 至2027年的各用途市場預測

  • 概要
  • 肺癌
  • 乳癌
  • 大腸癌
  • 黑色素瘤
  • 前列腺癌
  • 頭頸癌
  • 其他

第6章 至2027年的各終端用戶市場預測

  • 醫院
  • 癌症研究中心
  • 診療所

第7章 至2027年的各地區市場預測

  • 各地區市場預測
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 其他各國

第8章 定性分析

  • 波特五力分析
  • 促進因素與阻礙因素
  • 新興經濟的機會

第9章 主要企業

  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Medtronic plc.
  • Bristol-Myers Squibb
  • Novartis AG
  • Pfizer Inc.
  • Bayer AG
  • AstraZeneca Plc.
  • Eli Lilly and Company
  • Advaxis, Inc.

第10章 結論

附錄

目錄
Product Code: PHA0266

The world cancer immunotherapy market is expected to grow at a CAGR of 12.6% in the second half of the forecast period. The market reached $51.9bn in 2016, dominated by the monoclonal antibody segment which held 66.7% share of the market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 165-page report you will receive 95 tables and 94 figures- all unavailable elsewhere.

The 165-page report provides clear detailed insight into the world cancer-treating drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

World cancer immunotherapy market forecasts to 2027

  • This report also breaks down the revenue forecast for the world cancer immunotherapy market by Technology:
    • Monoclonal Antibodies
    • Cytokines & immunomodulators
    • Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report also breaks down the revenue forecast for the world cancer immunotherapy market by Application:
    • Lung Cancer
    • Breast Cancer
    • Colorectal cancer
    • Melanoma Cancer
    • Prostate Cancer
    • Head & Neck Cancer,
    • Others (Renal Cell Carcinoma, Cervical, Gastric, Lymphoma)

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report also breaks down the revenue forecast for the world cancer immunotherapy market by End User:
    • Hospitals
    • Cancer Research Centers
    • Clinics

Each submarket is further broken down by region: North America, South America, Europe, Asia-Pacific and ROW.

  • This report provides individual revenue forecasts to 2027 for these regional and national markets:
    • North America: US, Canada, Mexico
    • South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
    • Europe: The UK, Germany, France, Spain, Italy, Rest of Europe
    • Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
    • Rest of World: Middle East, Africa, Other Countries
  • This report discusses trends in the industry and assesses drivers and restraints, as well as opportunities and threats. It also includes porters five force analysis; threat of new entrants, power of suppliers, power of buyers, rivalry among competitors and threat of substituents.
  • Our study discusses the selected leading companies that are the major players in the cancer immunotherapy market:
    • AstraZeneca
    • Merck & Co., Inc. (Merck)
    • Novartis
    • Bristol-Myers Squibb (BMS)
    • Roche
    • Eli Lilly and Co.
    • Pfizer
    • Bayer
    • Adaxic Inc
    • Medtronic Plc

The report provides overviews of the companies, financial information, product portfolio, pipeline products and recent developments.

Visiongain's study is intended for anyone requiring commercial analyses for the world Cancer Immunotherapy market. You find data, trends and predictions.

Buy our report today Global Cancer Immunotherapy Market to 2027: Monoclonal Antibodies, Cytokines & Immunomodulators, Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy, Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Cancer Immunotherapy Market Overview
  • 1.2. Market Definition
  • 1.3. Research Methodology
  • 1.4. Primary Research
  • 1.5. Secondary Research
  • 1.6. Market Evaluation & Forecasting Methodology
  • 1.7. Global Cancer Immunotherapy Market Segmentation
  • 1.8. Overview of Findings
  • 1.9. Why You Should Read This Report
  • 1.10. How this report delivers?
  • 1.11. Key Questions Answered by This Analytical Report
  • 1.12. Frequently Asked Questions (FAQ)
  • 1.13. Who is This Report For?
  • 1.14. Associated Visiongain Reports
  • 1.15. About Visiongain

2. Introduction to Cancer Immunotherapy Market

3. Global Cancer Immunotherapy Market Forecast to 2027

4. Global Cancer Immunotherapy Market by Technology: Market Forecast to 2027

  • 4.1. Overview
  • 4.2. Monoclonal antibodies
  • 4.3. Cytokines & Immunomodulators
  • 4.4. Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

5. Global Cancer Immunotherapy Market by Application: Market Forecast to 2027

  • 5.1. Overview
  • 5.2. Lung Cancer
  • 5.3. Breast Cancer
  • 5.4. Colorectal Cancer
  • 5.5. Melanoma
  • 5.6. Prostate Cancer
  • 5.7. Head & Neck Cancer
  • 5.8. Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

6. Global Cancer Immunotherapy Market by End-User: Market Forecast to 2027

  • 6.1. Hospitals
  • 6.2. Cancer Research Centres
  • 6.3. Clinics

7. Regional Cancer Immunotherapy Market Forecasts to 2027

  • 7.1. Regional Cancer Immunotherapy Market Forecast 2016-2027
  • 7.2. North American Cancer Immunotherapy Market Forecast 2016-2027
    • 7.2.1. USA Cancer Immunotherapy Market Forecast 2016-2027
    • 7.2.2. Canada Cancer Immunotherapy Market Forecast 2016-2027
    • 7.2.3. Mexico Cancer Immunotherapy Market Forecast 2016-2027
  • 7.3. South American Cancer Immunotherapy Market Forecast 2016-2027
    • 7.3.1. Brazil Cancer Immunotherapy Market Forecast 2016-2027
    • 7.3.2. Argentina Cancer Immunotherapy Market Forecast 2016-2027
    • 7.3.3. Paraguay Cancer Immunotherapy Market Forecast 2016-2027
    • 7.3.4. Bolivia Cancer Immunotherapy Market Forecast 2016-2027
    • 7.3.5. Rest of South America Cancer Immunotherapy Market Forecast 2016-2027
  • 7.4. European Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.1. France Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.2. Germany Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.3. UK Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.4. Spain Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.5. Italy Cancer Immunotherapy Market Forecast 2016-2027
    • 7.4.6. Rest of Europe Cancer Immunotherapy Market Forecast 2016-2027
  • 7.5. Asia-Pacific Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.1. China Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.2. Japan Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.3. India Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.4. Australia Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.5. Thailand Cancer Immunotherapy Market Forecast 2016-2027
    • 7.5.6. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast 2016-2027
  • 7.6. Rest of World Cancer Immunotherapy Market Forecast 2016-2027
    • 7.6.1. Middle East Cancer Immunotherapy Market Forecast 2016-2027
    • 7.6.2. Africa Cancer Immunotherapy Market Forecast 2016-2027
    • 7.6.3. Other Countries Cancer Immunotherapy Market Forecast 2016-2027

8. Cancer Immunotherapy Market, Qualitative Analysis, 2016-2027

  • 8.1. Porter's Five Forces Analysis of the Cancer Immunotherapy Market 2016-2027
  • 8.2. Bargaining Power of Buyers (Low)
  • 8.3. Bargaining Power of Suppliers (High)
  • 8.4. Threat of New Entrants (Low)
  • 8.5. Threat of Substitute Products (High)
  • 8.6. Intensity of Competitive Rivalry (High)
  • 8.7. Drivers & Restrains
  • 8.8. Increasing Prevalence of Cancer
  • 8.9. Increasing Research in Cancer Immunotherapy
  • 8.10. High Cost of Cancer Immunotherapy
  • 8.11. Increasing Funding for the Cancer Research by Governmental Organisations
  • 8.12. Increasing Investment from Government, Public and Private Sector
  • 8.13. Increased Focus Towards Advanced Treatment Protocols
  • 8.14. Significant Unmet Need in Cancer Diagnosis
  • 8.15. Increased Awareness to Reduce Healthcare Costs
  • 8.16. Opportunities in Emerging Economies

9. Leading Companies in Cancer Immunotherapy Market

  • 9.1. F. Hoffmann-La Roche AG
  • 9.2. F. Hoffmann-La Roche AG: Company Overview
  • 9.3. F. Hoffmann-La Roche AG: Business Performance
  • 9.4. F. Hoffmann-La Roche AG: Product Portfolio
  • 9.5. F. Hoffmann-La Roche AG: Recent Developments
  • 9.6. Merck & Co., Inc.
  • 9.7. Merck & Co., Inc.: Company Overview
  • 9.8. Merck & Co., Inc.: Business Performance
  • 9.9. Merck & Co., Inc.: Product Portfolio
  • 9.10. Merck & Co., Inc.: Recent Development
  • 9.11. Medtronic plc.
  • 9.12. Medtronic plc.: Company Overview
  • 9.13. Medtronic plc.: Business Performance
  • 9.14. Medtronic plc.: Product Portfolio
  • 9.15. Medtronic plc.: Recent Developments
  • 9.16. Bristol-Myers Squibb
  • 9.17. Bristol-Myers Squibb: Company Overview
  • 9.18. Bristol-Myers Squibb: Product Portfolio
  • 9.19. Bristol-Myers Squibb: Recent Developments
  • 9.20. Novartis AG
  • 9.21. Novartis AG: Company Overview
  • 9.22. Novartis AG: Business Performance
  • 9.23. Novartis AG: Product Portfolio
  • 9.24. Novartis AG: Recent Developments
  • 9.25. Pfizer Inc.
  • 9.26. Pfizer Inc.: Company Overview
  • 9.27. Pfizer Inc.: Business Performance
  • 9.28. Pfizer Inc.: Product Portfolio
  • 9.29. Pfizer Inc.: Recent Developments
  • 9.30. Bayer AG
  • 9.31. Bayer AG: Company Overview
  • 9.32. Bayer AG: Business Performance
  • 9.33. Bayer AG: Product Portfolio
  • 9.34. Bayer AG: Recent Development
  • 9.35. AstraZeneca Plc.
  • 9.36. AstraZeneca Plc.: Company Overview
  • 9.37. AstraZeneca Plc.: Business Performance
  • 9.38. AstraZeneca Plc.: Product Portfolio
  • 9.39. Eli Lilly and Company
  • 9.40. Eli Lilly and Company: Company Overview
  • 9.41. Eli Lilly and Company: Business Performance
  • 9.42. Eli Lilly and Company: Product Portfolio
  • 9.43. Eli Lilly and Company: Recent Development
  • 9.44. Advaxis, Inc.
  • 9.45. Advaxis, Inc.: Recent Development
  • 9.46. Advaxis, Inc.: Business Performance
  • 9.47. Advaxis, Inc.: Recent Development

10. Conclusions

  • 10.1. Current Leading Segments
  • 10.2. Leading Regional Markets
  • 10.3. Emerging Markets
  • 10.4. The Future of the Market?

Table of Tables

  • Table 2.1. Worldwide Estimated Incidence and Prevalence of all Cancer Types, (2012)
  • Table 3.1. Global Cancer Immunotherapy Market Forecast ($m, AGR%, CAGR%) 2016-2027
  • Table 4.1. Global Cancer Immunotherapy Market Forecast, by Technology ($m, AGR%, CAGR%) 2016-2027
  • Table 4.2. Types of Monoclonal Antibodies
  • Table 4.3. Therapeutic Monoclonal Antibodies Approved by FDA in 2015
  • Table 4.4. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.5. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast, by Geography, ($bn, AGR%, CAGR%) 2016-2027
  • Table 4.6. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.7. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast, by Geography ($million, AGR%, CAGR%) 2016-2027
  • Table 4.8. Global Others Technologies for Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 4.9. Global Other Technologies for Cancer Immunotherapy Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.1. Top Cancer Type in 2012
  • Table 5.2. Global Cancer Immunotherapy Market, by Application ($m, AGR%, CAGR%) 2016-2027
  • Table 5.3. Types of Monoclonal Antibodies
  • Table 5.4. Global Cancer Immunotherapy Market for Lung Cancer, ($m, AGR%, CAGR) 2016-2027
  • Table 5.5. Global Cancer Immunotherapy Market for Lung Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.6. Global Cancer Immunotherapy Market for Breast Cancer, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.7. Global Cancer Immunotherapy Market for Breast Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.8. Global Cancer Immunotherapy Market for Colorectal Cancer, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.9. Global Cancer Immunotherapy Market for Colorectal Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.10. Global Cancer Immunotherapy Market for Melanoma Cancer, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.11. Global Cancer Immunotherapy Market for Melanoma Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.12. Global Cancer Immunotherapy Market for Prostate Cancer, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.13. Global Cancer Immunotherapy Market for Prostate Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.14. Global Cancer Immunotherapy Market for Head & Neck Cancer, ($m, AGR%, CAGR%) 2016-2027
  • Table 5.15. Global Cancer Immunotherapy Market for Head & Neck Cancer, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 5.16. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma), ($m, AGR%, CAGR%) 2016-2027
  • Table 5.17. Global Cancer Immunotherapy Market for Other Cancer Types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma), by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 6.1. Global Cancer Immunotherapy Market, by End-User ($m, AGR%, CAGR%) 2016-2027
  • Table 6.2. Global Cancer Immunotherapy Market Forecast for Hospital ($m, AGR%, CAGR%) 2016-2027
  • Table 6.3. Global Cancer Immunotherapy Market Forecast for Hospital, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 6.4. Funding Received by NCI ($m)
  • Table 6.5. Current Grants by Cancer Type as of August 2016
  • Table 6.6. Global Cancer Immunotherapy Market for Cancer Research Centres, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.7. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 6.8. Global Cancer Immunotherapy Market Forecast for Clinic, ($m, AGR%, CAGR%) 2016-2027
  • Table 6.9. Global Cancer Immunotherapy Market Forecast for Clinic, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 7.1. Global Cancer Immunotherapy Market Forecast, by Geography ($m, AGR%, CAGR%) 2016-2027
  • Table 7.2. North America Cancer Immunotherapy Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 7.3. USA Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.4. Canada Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.5. Mexico Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.6. South America Cancer Immunotherapy Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 7.7. Brazil Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.8. Argentina Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.9. Paraguay Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.10. Bolivia Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.11. Rest of South America Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.12. European Cancer Immunotherapy Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 7.13. France Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.14. Germany Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.15. UK Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.16. Spain Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.17. Italy Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.18. Rest of European Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.19. Asia-Pacific Cancer Immunotherapy Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 7.20. China Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.21. Japan Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.22. India Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.23. Australia Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.24. Thailand Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.25. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.26. Rest of World Cancer Immunotherapy Market Forecast, by Country ($m, AGR%, CAGR%) 2016-2027
  • Table 7.27. Middle East Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.28. Africa Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 7.29. Other Countries Cancer Immunotherapy Market Forecast, ($m, AGR%, CAGR%) 2016-2027
  • Table 9.1. F. Hoffmann-La Roche AG: Company Overview
  • Table 9.2. F. Hoffmann-La Roche AG: Product Portfolio
  • Table 9.3. F. Hoffmann-La Roche AG: Recent Developments
  • Table 9.4. Merck & Co., Inc.: Company Overview
  • Table 9.5. Merck & Co., Inc.: Product Portfolio
  • Table 9.6. Merck & Co., Inc.: Recent Development
  • Table 9.7. Medtronic plc.: Company Overview
  • Table 9.8. Medtronic plc.: Product Portfolio
  • Table 9.9. Medtronic plc.: Recent Developments
  • Table 9.10. Bristol-Myers Squibb: Company Overview
  • Table 9.11. Bristol-Myers Squibb: Product Portfolio
  • Table 9.12. Bristol-Myers Squibb: Recent Developments
  • Table 9.13. Novartis AG: Company Overview
  • Table 9.14. Novartis AG: Product Portfolio
  • Table 9.15. Novartis AG: Recent Developments
  • Table 9.16. Pfizer Inc.: Company Overview
  • Table 9.17. Pfizer Inc.: Product Portfolio
  • Table 9.18. Pfizer Inc.: Recent Development
  • Table 9.19. Bayer AG: Company Overview
  • Table 9.20. Bayer AG: Product Portfolio
  • Table 9.21. Bayer AG: Recent Development
  • Table 9.22. AstraZeneca Plc.: Company Overview
  • Table 9.23. AstraZeneca Plc.: Product Portfolio
  • Table 9.24. Eli Lilly and Company: Company Overview
  • Table 9.25. Eli Lilly and Company: Product Portfolio
  • Table 9.26. Eli Lilly and Company: Recent Development
  • Table 9.27. Advaxis, Inc.: Company Overview
  • Table 9.28. Advaxis, Inc.: Recent Developments
  • Table 10.1. Worldwide Estimated Prevalence of Cancer, 2012

Table of Figures

  • Figure 1.1. Cancer immunotherapy Market Segmentation
  • Figure 2.1. Top winning Strategies of Market Players in Cancer Immunotherapy, 2014-2016
  • Figure 3.1. Cancer Immunotherapy Market, by Technology, ($m), 2016-2027
  • Figure 3.2. Cancer Immunotherapy Market, by Application, ($m), 2016-2027
  • Figure 3.3. Cancer Immunotherapy Market, by End-User, ($m), 2016-2027
  • Figure 4.1. Cancer Immunotherapy Market, by Technology, Market Share (%), 2016
  • Figure 4.2. Cancer Immunotherapy Market, by Technology, Forecast ($bn) 2016-2027
  • Figure 4.3. Global Monoclonal Antibodies for Cancer Immunotherapy Market Forecast, by Geography, ($m) 2016-2027
  • Figure 4.4. Global Cytokines & Immunomodulators for Cancer Immunotherapy Market Forecast, by Geography, ($m) 2016-2027
  • Figure 4.5. Global Other Technologies for Cancer Immunotherapy Market Forecast, by Geography, ($m) 2016-2027
  • Figure 5.1. Global Cancer Immunotherapy Market, by Application, ($m) 2016-2027
  • Figure 5.2. Global Cancer Immunotherapy Market, by Application, Market Share (%), 2016
  • Figure 5.3. Global Cancer Immunotherapy Market for Lung Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.4. Global Cancer Immunotherapy Market for Breast Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.5. Global Cancer Immunotherapy Market for Colorectal Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.6. Global Cancer Immunotherapy Market for Melanoma Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.7. Global Cancer Immunotherapy Market for Prostate Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.8. Global Cancer Immunotherapy Market for Head & Neck Cancer Forecast, by Geography ($m) 2016-2027
  • Figure 5.9. Global Cancer Immunotherapy Market for Other Cancer types (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma) Forecast, by Geography ($m) 2016-2027
  • Figure 6.1. Global Cancer Immunotherapy Market Forecast, by End-User, ($m) 2016-2027
  • Figure 6.2. Global Cancer Immunotherapy Market, by End-User, Market Share (%), 2016
  • Figure 6.3. Global Cancer Immunotherapy Market Forecast for Hospital, by Geography, ($m) 2016-2027
  • Figure 6.4. Global Cancer Immunotherapy Market Forecast for Cancer Research Centres, by Geography ($m) 2016-2027
  • Figure 6.5. Global Cancer Immunotherapy Market Forecast for Clinic, by Geography ($m) 2016-2027
  • Figure 7.1. Global Cancer Immunotherapy Market Forecast, by Geography, by Geography ($m) 2016-2027
  • Figure 7.2. Global Cancer Immunotherapy Market Forecast, by Geography, Market Share (%), 2016
  • Figure 7.3. North America Cancer Immunotherapy Market Forecast, by Country ($m) 2016-2027
  • Figure 7.4. North America Cancer Immunotherapy Market, by Country, Market Share (%), 2016
  • Figure 7.5. USA Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.6. Estimation of diagnosis of Canadian Cancer Immunotherapy
  • Figure 7.7. Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.8. Mexico Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.9. South America Cancer Immunotherapy Market Forecast, by Country ($m) 2016-2027
  • Figure 7.10. South America Cancer Immunotherapy Market, by Country, Market Share (%), 2016
  • Figure 7.11. Brazil Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.12. Argentina Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.13. Paraguay Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.14. Bolivia Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.15. Rest of South America Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.16. Europe Cancer Immunotherapy Market Forecast, by Country ($m) 2016-2027
  • Figure 7.17. Europe Cancer Immunotherapy Market, by Country, Market Share (%), 2016
  • Figure 7.18. France Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.19. Germany Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.20. UK Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.21. Spain Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.22. Italy Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.23. Rest of Europe Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.24. Asia-Pacific Cancer Immunotherapy Market Forecast, by Country ($m) 2016-2027
  • Figure 7.25. Asia-Pacific Cancer Immunotherapy Market, Market Share (%), 2016
  • Figure 7.26. Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.27. Japan Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.28. India Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.29. Australia Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.30. Thailand Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.31. Rest of Asia-Pacific Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.32. RoW Cancer Immunotherapy Market Forecast, by Country ($m) 2016-2027
  • Figure 7.33. Rest of World Cancer Immunotherapy Market, by Country, Market Share (%), 2016
  • Figure 7.34. Middle East Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.35. Africa Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 7.36. Other Countries Cancer Immunotherapy Market Forecast ($m) 2016-2027
  • Figure 8.1. Porter's Five Forces Analysis of the Cancer Immunotherapy Market
  • Figure 9.1. F. Hoffmann-La Roche AG: Historical Revenue, ($m), 2012-2016
  • Figure 9.2. F. Hoffmann-La Roche AG, Product Segments Share (%), 2016
  • Figure 9.3. F. Hoffmann-La Roche AG, Geographical Presence Share (%), 2016
  • Figure 9.4. Merck & Co., Inc.: Historical Revenue, ($m), 2012-2016
  • Figure 9.5. Merck & Co., Inc., Product Segments Share (%), 2016
  • Figure 9.6. Merck & Co., Inc., Geographical Presence Share (%), 2016
  • Figure 9.7. Medtronic plc., Historical Revenue, ($m), 2012-2016
  • Figure 9.8. Medtronic plc., Product Segments Share (%), 2016
  • Figure 9.9. Medtronic plc., Geographical Presence Share (%), 2016
  • Figure 9.10. Bristol-Myers Squibb, Historical Revenue, ($m), 2012-2016
  • Figure 9.11. Bristol-Myers Squibb, Product Segments Share (%), 2016
  • Figure 9.12. Bristol-Myers Squibb, Geographical Presence Share (%), 2016
  • Figure 9.13. Novartis AG, Historical Revenue, ($m), 2012-2016
  • Figure 9.14. Novartis AG, Product Segments Share (%), 2016
  • Figure 9.15. Novartis AG, Geographical Presence Share (%), 2016
  • Figure 9.16. Pfizer Inc., Historical Revenue, ($m), 2012-2016
  • Figure 9.17. Pfizer Inc., Product Segments Share (%), 2016
  • Figure 9.18. Pfizer Inc., Geographical Presence Share (%), 2016
  • Figure 9.19. Bayer AG, Historical Revenue, ($m), 2012-2016
  • Figure 9.20. Bayer AG, Product Segments Share (%), 2016
  • Figure 9.21. Bayer AG, Geography Presence Share (%), 2016
  • Figure 9.22. AstraZeneca Plc., Historical Revenue, ($m), 2012-2016
  • Figure 9.23. AstraZeneca Plc., Product Segments Share (%), 2016
  • Figure 9.24. AstraZeneca Plc., Geographical Presence Share (%), 2016
  • Figure 9.25. Eli Lilly and Company, Historical Revenue, ($m), 2012-2016
  • Figure 9.26. Eli Lilly and Company, Product Segments Share (%), 2016
  • Figure 9.27. Eli Lilly and Company, Geographical Presence Share (%), 2016
  • Figure 9.28. Advaxis, Inc., Historical Revenue, ($m), 2014-2016
  • Figure 9.29. Advaxis, Inc., Product Segments Share (%), 2016
  • Figure 10.1. World Cancer Immunotherapy, by Technology, ($m), 2016-2027
  • Figure 10.2. World Cancer Immunotherapy, by Application, ($m), 2016-2027
  • Figure 10.3. World Cancer Immunotherapy, by End-User, ($m), 2016-2027
  • Figure 10.4. World Cancer Immunotherapy, by Geography, ($m) 2016-2027

Companies Listed

  • Adaptimmune Therapeutics Plc
  • Adaxis Inc
  • Admune Therapeutics
  • American Cancer Society
  • Astrazeneca Plc
  • Bayer AG
  • BioNTech AG
  • Biothera
  • Bristol Myers Squibb
  • Eli Lilly and Co.
  • European Medicines Agency (EMA)
  • Food and Drud Administration (FDA)
  • Genomic Health Inc
  • German Cancer Research Center
  • GlaxoSmithKline (GSK)
  • Janssen Biotech Inc
  • Medtronic Plc
  • Merck & Co.
  • Merck KGaA
  • National Cancer Institute
  • Novartis AG
  • Parker Institute for Cancer Immunotherapy
  • Pfizer Inc
  • Qiagen
  • Roche
  • Sellas
  • World Health Organisation (WHO
Back to Top